ACTIVE

ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE

Financial year 2025 · closed on 31/12/2025
Net result
432,3 k €
+49.2% YoY
Revenue
10,4 M €
+4.3% YoY
Equity
6,7 M €
+6.9% YoY
Workforce
28,6 ETP
+8.7% YoY

What does ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE do?

ASSOCIATION GENERALE DE L'INDUSTRIE DU MEDICAMENT - ALGEMENE VERENIGING VAN DE GENEESMIDDELENINDUSTRIE is a Non-profit organization incorporated in 1966. Its registered office is in Bruxelles. It employs on average 28,6 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0407.622.902
Incorporation
26/10/1966
Legal form
Non-profit organization
Registered office
Cantersteen 47
1000 Bruxelles · BruxellesSee on map
Latest accounts
31/12/2025
Average workforce
28,6 ETP
Joint committees (2)
  • 200
  • 335
Signals
ProfitableSolid equityLow riskGood liquidityPositive cashflowPositive EBITDAHealthy social debtsHigh revenue
Health score
Available with a Rovalta subscriptionTry for 7 days
Recommended credit limit
✦ Verdict · Analyst summary
Financials

Trend over 19 financial years

2025202420232022202120202019201820172016201520142013201220112010200920082007
Income statement
Revenue10,4 M €9,9 M €9,8 M €8,8 M €7,6 M €7,8 M €6,1 M €5,9 M €5,7 M €5,7 M €5,5 M €5,4 M €5 M €5,3 M €5 M €5,3 M €4,9 M €5,1 M €5 M €
EBITDA443 k €292,5 k €699,8 k €943,9 k €1,3 M €480 k €149,9 k €102,9 k €24,4 k €855,6 k €648,9 k €-351,2 k €-752,3 k €-47,5 k €550,8 k €649 k €664,8 k €143,2 k €167,9 k €
Operating result262 k €192,2 k €611,9 k €824,7 k €1,2 M €347,4 k €22 k €18,6 k €-39,4 k €660,8 k €438,9 k €-162,9 k €-1,2 M €-278,8 k €38,6 k €410 k €528,4 k €68,6 k €100,7 k €
Net result432,3 k €289,6 k €788,8 k €548,6 k €1,2 M €381,5 k €22,7 k €11,9 k €-43,7 k €657,2 k €428,2 k €-239,8 k €-1,7 M €-426 k €27,3 k €428,9 k €607,1 k €211,1 k €198,6 k €
Balance sheet
Equity6,7 M €6,3 M €6 M €5,2 M €4,7 M €3,5 M €3,1 M €3,1 M €3,1 M €3,1 M €2,5 M €2,1 M €2,3 M €4 M €4,4 M €4,4 M €4 M €3,4 M €3,2 M €
Total assets9,3 M €8,5 M €8 M €6,6 M €5,4 M €4,5 M €4,5 M €4 M €3,8 M €3,7 M €3,5 M €2,9 M €3,1 M €5,2 M €5,5 M €6 M €5,6 M €5,2 M €5,4 M €
Cash4,8 M €3,5 M €4,1 M €3,2 M €2,6 M €2,8 M €2,8 M €2,5 M €2 M €2,3 M €2,2 M €1,6 M €411 k €633,3 k €2,2 M €2 M €2,4 M €2,8 M €1,8 M €
Debts1,7 M €1,7 M €1,6 M €1,3 M €718 k €959,9 k €744,1 k €845,9 k €718 k €541,9 k €468,8 k €500,7 k €739,9 k €1,1 M €1 M €1,2 M €822,5 k €1 M €1,3 M €
Other
Workforce28,6 ETP26,3 ETP24,9 ETP24,4 ETP25,7 ETP25,4 ETP24,7 ETP24,2 ETP24,7 ETP24,3 ETP24,7 ETP23,3 ETP23,5 ETP22,8 ETP22,1 ETP19,0 ETP22,9 ETP23,0 ETP22,8 ETP
Estimate

Indicative valuation

As an indication, this company is worth

between 5 M€ and 10 M€
See the valuation
Governance

Board of directors

Seen on filing of 31/12/2025 · 17 active · 138 ended

Active mandates

Almirall

Director · since 11 juin 2025 · until 07 juin 2028 · 0403.090.131

Represented by Gregory Paton

Active
AMGEN

Director · since 11 juin 2025 · until 07 juin 2028 · 0439.652.401

Represented by Sara Schaufelberger

Active
MSD BELGIUM

Director · since 11 juin 2025 · until 07 juin 2028 · 0406.820.770

Represented by Katrien De Vos

Active
ROCHE

Director · since 11 juin 2025 · until 07 juin 2028 · 0403.088.151

Represented by Marie-José Borst

Active
S.A. NOVO NORDISK PHARMA N.V.

Director · since 11 juin 2025 · until 07 juin 2028 · 0414.695.586

Represented by Axel De Muyt

Active
TAKEDA BELGIUM

Director · since 11 juin 2025 · until 07 juin 2028 · 0403.054.202

Represented by Bruno Rabilier

Active
UCB PHARMA

Vice-chairman of the board of directors · since 11 juin 2025 · until 07 juin 2028 · 0403.096.168

Represented by Xavier Hormaechea

Active
ABBVIE

Director · since 13 mars 2024 · until 09 juin 2027 · 0845.096.860

Represented by Renaud Decroix

Active
Bayer

Director · since 13 mars 2024 · until 09 juin 2027 · 0404.754.571

Represented by Niels Hessmann

Active
Eli Lilly Benelux

Chairman of the board of directors · since 13 mars 2024 · until 09 juin 2027 · 0406.754.454

Represented by Frédéric Clais

Active
GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline

Director · since 13 mars 2024 · until 09 juin 2027 · 0403.066.474

Represented by Emmanuelle Boishardy

Active
Pfizer

Director · since 13 mars 2024 · until 09 juin 2027 · 0401.994.823

Represented by David Lepoittevin

Active
AstraZeneca

Director · since 22 mars 2023 · until 03 juin 2026 · 0400.165.679

Represented by Angela Thompson

Active
BRISTOL - MYERS SQUIBB BELGIUM

Director · since 22 mars 2023 · until 03 juin 2026 · 0403.075.184

Represented by Sally McNab

Active
Janssen-Cilag

Director · since 22 mars 2023 · until 03 juin 2026 · 0415.283.427

Represented by Roxana Botea

Active
NOVARTIS PHARMA

Director · since 22 mars 2023 · until 03 juin 2026 · 0459.093.476

Represented by Federico Mambretti

Active
SANOFI BELGIUM

Director · since 22 mars 2023 · until 03 juin 2026 · 0464.435.901

Represented by Bart Vermeulen

Active

Ended mandates

AstraZeneca

Director · since 22 mars 2023 · until 18 mars 2026 · 0400.165.679

Represented by Keira Driansky

Ended
AstraZeneca

Director · since 22 mars 2023 · until 10 juin 2026 · 0400.165.679

Represented by Angela Thompson

Ended
BRISTOL - MYERS SQUIBB BELGIUM

Director · since 22 mars 2023 · until 18 mars 2026 · 0403.075.184

Represented by Sally McNab

Ended
BRISTOL - MYERS SQUIBB BELGIUM

Director · since 22 mars 2023 · until 10 juin 2026 · 0403.075.184

Represented by Sally McNab

Ended
At this address

Other companies at this address

CompanyCBE no.
13 ANALYTICSActive
0793.625.987
0506.804.115
0778.940.781
1034.146.494
1007.736.067
1010.584.897
Ahead DigitalActive
0867.212.266
AlexandriteFActive
0804.051.905
0780.685.989
0696.869.477
AMBOS LawActive
0550.946.241
AMCAHubActive
1025.495.282
0409.404.336
0800.049.664
0742.927.255
0733.604.961
Aricoma SystemsActive
0767.591.979
Arts 28Active
1025.504.487
0453.963.760
ATowerHubActive
1025.504.388
Annual accounts

Full financial information

202520242023202220212020
Type of accountFull modelFull modelFull modelFull modelFull modelFull model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date16/06/202617/06/202529/03/202424/04/202305/04/202223/03/2021
General meeting03/06/202611/06/202513/03/202422/03/202323/03/202217/03/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls
Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days
Filings

Annual accounts filings

20 filings with the NBB

ModelClosingGeneral meetingFiledLanguageDocument
Full model31/12/202503/06/202616/06/2026DutchPDF
Full model31/12/202411/06/202517/06/2025DutchPDF
Full model31/12/202313/03/202429/03/2024DutchPDF
Full model31/12/202222/03/202324/04/2023DutchPDF
Full model31/12/202123/03/202205/04/2022DutchPDF
Full model31/12/202017/03/202123/03/2021DutchPDF
Full model31/12/201913/05/202008/06/2020DutchPDF
Full model31/12/201827/03/201915/04/2019DutchPDF
Full model31/12/201723/03/201827/03/2018DutchPDF
Full model31/12/201624/03/201710/04/2017DutchPDF
Full model31/12/201518/03/201624/03/2016DutchPDF
Full model31/12/201427/03/201523/04/2015DutchPDF
Full model31/12/201328/03/201414/04/2014DutchPDF
Full model31/12/201222/03/201329/11/2013DutchPDF
Full model31/12/201123/03/201229/11/2013DutchPDF
Full model31/12/201026/03/201129/12/2011DutchPDF
Full model31/12/200926/03/201022/12/2011DutchPDF
Full model31/12/200827/03/200931/08/2009DutchPDF
Full model31/12/200721/03/200821/09/2009DutchPDF
Full model31/12/200630/03/200706/12/2007DutchPDF
Estimate

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 5 M€ and 10 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2025 · 17 active · 138 ended

Active mandates

Almirall

Director · since 11 juin 2025 · until 07 juin 2028 · 0403.090.131

Represented by Gregory Paton

Active
AMGEN

Director · since 11 juin 2025 · until 07 juin 2028 · 0439.652.401

Represented by Sara Schaufelberger

Active
MSD BELGIUM

Director · since 11 juin 2025 · until 07 juin 2028 · 0406.820.770

Represented by Katrien De Vos

Active
ROCHE

Director · since 11 juin 2025 · until 07 juin 2028 · 0403.088.151

Represented by Marie-José Borst

Active
S.A. NOVO NORDISK PHARMA N.V.

Director · since 11 juin 2025 · until 07 juin 2028 · 0414.695.586

Represented by Axel De Muyt

Active
TAKEDA BELGIUM

Director · since 11 juin 2025 · until 07 juin 2028 · 0403.054.202

Represented by Bruno Rabilier

Active
UCB PHARMA

Vice-chairman of the board of directors · since 11 juin 2025 · until 07 juin 2028 · 0403.096.168

Represented by Xavier Hormaechea

Active
ABBVIE

Director · since 13 mars 2024 · until 09 juin 2027 · 0845.096.860

Represented by Renaud Decroix

Active
Bayer

Director · since 13 mars 2024 · until 09 juin 2027 · 0404.754.571

Represented by Niels Hessmann

Active
Eli Lilly Benelux

Chairman of the board of directors · since 13 mars 2024 · until 09 juin 2027 · 0406.754.454

Represented by Frédéric Clais

Active
GlaxoSmithKline Pharmaceuticals, en abrégé GlaxoSmithKline

Director · since 13 mars 2024 · until 09 juin 2027 · 0403.066.474

Represented by Emmanuelle Boishardy

Active
Pfizer

Director · since 13 mars 2024 · until 09 juin 2027 · 0401.994.823

Represented by David Lepoittevin

Active
AstraZeneca

Director · since 22 mars 2023 · until 03 juin 2026 · 0400.165.679

Represented by Angela Thompson

Active
BRISTOL - MYERS SQUIBB BELGIUM

Director · since 22 mars 2023 · until 03 juin 2026 · 0403.075.184

Represented by Sally McNab

Active
Janssen-Cilag

Director · since 22 mars 2023 · until 03 juin 2026 · 0415.283.427

Represented by Roxana Botea

Active
NOVARTIS PHARMA

Director · since 22 mars 2023 · until 03 juin 2026 · 0459.093.476

Represented by Federico Mambretti

Active
SANOFI BELGIUM

Director · since 22 mars 2023 · until 03 juin 2026 · 0464.435.901

Represented by Bart Vermeulen

Active

Ended mandates

AstraZeneca

Director · since 22 mars 2023 · until 18 mars 2026 · 0400.165.679

Represented by Keira Driansky

Ended
AstraZeneca

Director · since 22 mars 2023 · until 10 juin 2026 · 0400.165.679

Represented by Angela Thompson

Ended
BRISTOL - MYERS SQUIBB BELGIUM

Director · since 22 mars 2023 · until 18 mars 2026 · 0403.075.184

Represented by Sally McNab

Ended
BRISTOL - MYERS SQUIBB BELGIUM

Director · since 22 mars 2023 · until 10 juin 2026 · 0403.075.184

Represented by Sally McNab

Ended
Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days
Belgian Official Gazette

Belgian Official Gazette publications

  • Mandates27/01/2026
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates27/01/2026
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates17/11/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates17/11/2025
    ONTSLAGEN - BENOEMINGEN
    PDF
  • Mandates22/07/2025
    DEMISSIONS, NOMINATIONS - ASSEMBLEE GENERALE
    PDF
  • Mandates22/07/2025
    ONTSLAGEN - BENOEMINGEN - ALGEMENE VERGADERING
    PDF
  • Mandates04/04/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates04/04/2025
    ONTSLAGEN - BENOEMINGEN
    PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 2025432,3 k €
  2. 2024
    Annual accounts 2024289,6 k €
  3. 2023
    Annual accounts 2023788,8 k €
  4. 2022
    Annual accounts 2022548,6 k €
  5. 2021
    Annual accounts 20211,2 M €
  6. 2020
    Annual accounts 2020381,5 k €
  7. 2019
    Annual accounts 201922,7 k €
  8. 2018
    Annual accounts 201811,9 k €
  9. 2017
    Annual accounts 2017-43,7 k €
  10. 2016
    Annual accounts 2016657,2 k €
  11. 2015
    Annual accounts 2015428,2 k €
  12. 2014
    Annual accounts 2014-239,8 k €
  13. 2013
    Annual accounts 2013-1,7 M €
  14. 2012
    Annual accounts 2012-426 k €
  15. 2011
    Annual accounts 201127,3 k €
  16. 2010
    Annual accounts 2010428,9 k €
  17. 2009
    Annual accounts 2009607,1 k €
  18. 2008
    Annual accounts 2008211,1 k €
  19. 2007
    Annual accounts 2007198,6 k €
  20. 26/10/1966
    IncorporationNon-profit organization